The COPD drug you breathe, not puff

Pick up an inhaler and try to use it the way the label says. Exhale fully. Seal your lips. Press the canister and breathe in slow and deep at the exact same instant, then hold for ten seconds. Now imagine doing that at 74, with arthritic hands, weak lungs, and a memory that skips. Study after study finds that a large share of chronic obstructive pulmonary disease patients get this wrong - and a drug that never reaches the lung is a drug that never worked. AeroRx Therapeutics built a company around that quiet, unglamorous failure.

The San Diego biopharma, founded in 2023, has one deceptively simple idea: for the patients who can't operate a hand-held inhaler, stop asking them to. Deliver the medicine as a mist through a nebulizer - the machine that already sits in hospitals, nursing homes, and living rooms - and let people breathe it in over a few normal minutes. No coordination, no breath-hold, no dexterity test. Its lead candidate, AERO-007, is designed to be the first dual bronchodilator you nebulize instead of puff.

01 / THE PROBLEMThe patients inhalers leave behind

COPD is one of the leading causes of death in the United States, and unlike many chronic diseases its incidence keeps climbing as the population ages. Treatment guidelines have converged on a clear first-line answer: dual bronchodilation, pairing a long-acting beta-agonist (LABA) with a long-acting muscarinic antagonist (LAMA) to keep airways open. The catch is delivery. Nearly every LABA/LAMA combination on the market ships inside a hand-held inhaler that assumes steady hands, good breath control, and reliable technique.

For a big slice of the moderate-to-severe population, those assumptions don't hold. More than 16 million Americans carry a COPD diagnosis, and the disease skews old: many patients contend with tremor, weak grip strength, low inspiratory flow, or cognitive decline that turns a routine puff into a coin flip. When the technique fails, the dose fails with it, and the patient and physician are often left blaming the drug rather than the delivery. AeroRx's principal investigator, Prof. Dave Singh of the University of Manchester, put the gap plainly.

That sentence is the whole business case. The nebulizer market exists, the two drugs exist, the guidelines point to the combination - but nobody had put a fixed-dose LABA/LAMA into a form the machine can deliver. AeroRx is trying to be the one that does.

02 / THE PRODUCTWhat AERO-007 actually is

AERO-007 is a fixed-dose solution combining two FDA-approved bronchodilators - indacaterol, a LABA, and glycopyrrolate, a LAMA - formulated to run through a standard jet nebulizer, the kind already cleared for use. There is a deliberate cleverness to that choice. The company is not inventing new chemistry and betting a decade on whether the molecules work; those questions were answered years ago. The harder, narrower problem AeroRx took on is delivery: can you formulate these two drugs so a nebulizer turns them into a mist that reaches deep into the airways, at the right dose, safely?

In July 2025, AeroRx reported topline results from a Phase 2a study: a randomized, double-blind, placebo-controlled, single-dose, three-period crossover trial in 16 adults with moderate-to-severe COPD. Both the low and high doses produced statistically significant improvements in FEV1 - the standard measure of how much air a patient can force out in one second - versus placebo, with rapid onset and bronchodilation sustained through 24 hours. It was well tolerated, and systemic drug exposure looked comparable to the approved components on their own.

03 / THE FOUNDERA repeat operator's third act

AeroRx is led by co-founder and CEO Ahmet Tutuncu, MD, PhD, who has spent roughly three decades in respiratory and critical-care drug development. This is not his first nebulizer. He previously co-founded Elevation Pharmaceuticals and Patara Pharma - both later acquired - and his track record includes three drug approvals, among them Lonhala Magnair, a nebulized COPD product. He has, in other words, walked this exact path before, which is part of why investors gave a company with a handful of employees $21 million.

Tutuncu's read on the market is unsentimental. COPD, he argues, is a high-unmet-need disease where the sickest patients get the least usable devices, and where big pharma keeps writing large checks - Merck and GSK have spent billions acquiring COPD developers. His pitch is that the nebulizer, dismissed as old and clunky, is precisely the underserved lane.

04 / THE MODELSmall team, derisked by design

AeroRx operates lean - on the order of three employees - out of the Avalon BioVentures accelerator in La Jolla. The structure is deliberate: a veteran core leaning on outsourced clinical development rather than a big payroll, financed round by round with the aim of reaching late-stage data or an acquisition. That is the standard playbook for a certain kind of specialist biotech, and Tutuncu has run it to exit twice.

The reformulation strategy changes the risk math. Because AERO-007 combines drugs the FDA already approved, the central uncertainty is delivery and formulation, not fundamental biology. That narrows the questions a trial has to answer and shortens the odds an investor is underwriting. It is the smart, boring bet - and the boring bets are often the ones that pay.

It also clarifies who the customer is. AeroRx isn't chasing every COPD patient; the ones already well served by inhalers have plenty of options. The target is narrower and more defensible - the moderate-to-severe patients who need dual bronchodilation but struggle with hand-held devices, and the pulmonologists, primary-care physicians, and health systems already reaching for a nebulizer to treat them. Build a drug the machine in the room can deliver, and you meet demand that the crowded inhaler shelf has never actually filled.

05 / THE PIPELINEBeyond the lead drug

AERO-007 is the front-runner, but not the whole company. Behind it sits AERO-111, a nebulized triple-combination therapy that adds an inhaled corticosteroid (an ICS) to the LABA/LAMA pairing - a step up for COPD patients who need anti-inflammatory treatment on top of bronchodilation. It's in earlier, IND-enabling development. The logic is a franchise: establish the nebulized-combination format with the dual drug, then extend it to the triple.

The $21 million Series A, announced October 7, 2025 and led by Avalon BioVentures with Correlation Ventures and Alexandria Venture Investments, is earmarked to carry AERO-007 into late-stage clinical development - the expensive, decisive stretch between a promising Phase 2a and a drug regulators will approve. Avalon's Jay Lichter, PhD, sits on the investor side of a company his firm also incubated.

06 / THE STAKESWhat has to go right

None of this is finished. Phase 2a was small - 16 patients, a single dose, a crossover design built to read a signal, not to prove a drug. The value is in the late-stage trials the Series A is meant to fund, and respiratory development has humbled better-funded teams. A positive early readout narrows the odds; it doesn't settle them. AeroRx's advantage is that the biggest scientific questions were retired before it started, and that its founder has taken nebulized respiratory drugs through approval before.

Strip away the jargon and AeroRx is a bet on a very human observation: the best medicine is the one a patient can actually take. In a category obsessed with new molecules, a small San Diego team decided the real gap was the last few inches - from the device to the lung - and built a company to close it.